Vaccine manufacturer Moderna said Monday that a booster dose of its coronavirus vaccine significantly raised antibody levels against the omicron variant, amid growing concerns about its rapid spread in the United States.
Those antibodies “should provide some good level of protection as we go into the holiday season,” Paul Burton, Moderna’s chief medical officer, said in an interview.
Federal health officials warned this weekend, ahead of Christmas and New Year’s gatherings, that the United States could face record levels of coronavirus cases in the coming days. New York state has for three straight days reported record case numbers, and officials said the country could soon face the same fate.
About half of coronavirus cases nationally are of the omicron variant, Anthony S. Fauci, the country’s top infectious-disease expert, said Sunday on CNN. Because of omicron, the United States could soon reach 1 million new cases each day, Francis Collins, director of the National Institutes of Health, told CBS on Sunday.
“The big question is, are those million cases going to be sick enough to need health care and especially hospitalization?” Collins said. “We’re just holding our breath to see how severe this will be.”
Burton said that while Moderna did not yet have clinical data to speak to its vaccine’s protection against hospitalization and death, Monday’s data was “very reassuring because we’ve seen time and time again … that the vaccine is highly effective at preventing infection, hospitalization and death due to covid.”
Moderna is still pursuing an omicron-targeted vaccine, though its statement said that given the variant’s rapid spread, the company’s “first line of defense against omicron” would be a booster of its existing vaccine. Its omicron-specific vaccine candidate will advance to clinical trials early next year, the company said.
The current vaccine, Burton said, is “what we have right now, as we’re heading into the eye of the storm of omicron.”
Moderna also announced that a dose double the size of a normal booster, equivalent to that used in the main shots and in the third dose given primarily to immunocompromised people, raised antibody levels by 83 times.
The Centers for Disease Control and Prevention recommends this third, “primary shot” of the vaccine for people who are moderately or severely immunocompromised, such as those undergoing cancer treatment, taking immunosuppressing medication, or living with advanced or untreated HIV. Other vulnerable populations, such as the elderly and people who work in high-risk settings, were instead among the first to be eligible for booster shots.
The “exceptional” response from the larger dose, Burton said, could signal to officials that a higher dose may be useful in “certain high-risk individuals.”
Many Americans have yet to get a booster shot: About 18 percent of the U.S. population has had one, according to CDC data. About 61 percent of Americans have been fully vaccinated.
Coronavirus: What you need to know
End of the public health emergency: The Biden administration ended the public health emergency for the coronavirus pandemic on May 11, just days after WHO said it would no longer classify the coronavirus pandemic as a public health emergency. Here’s what the end of the covid public health emergency means for you.
Tracking covid cases, deaths: Covid-19 was the fourth leading cause of death in the United States last year with covid deaths dropping 47 percent between 2021 and 2022. See the latest covid numbers in the U.S. and across the world.
The latest on coronavirus boosters: The FDA cleared the way for people who are at least 65 or immune-compromised to receive a second updated booster shot for the coronavirus. Here’s who should get the second covid booster and when.
New covid variant: A new coronavirus subvariant, XBB. 1.16, has been designated as a “variant under monitoring” by the World Health Organization. The latest omicron offshoot is particularly prevalent in India. Here’s what you need to know about Arcturus.
Would we shut down again? What will the United States do the next time a deadly virus comes knocking on the door?
For the latest news, sign up for our free newsletter.